文献速递肺栓塞与肺血管病呼吸危重症与机械通气

肾移植患者肺动脉压纵向轨迹与临床结局

Longitudinal Pulmonary Arterial Pressure Trajectories and Clinical Outcome in Kidney Transplantation Patients.
PubMed 文献 · Chest · 2025-05-29

该回顾性研究分析退伍军人健康系统631例肾移植前后接受超声心动图评估肺动脉压的终末期肾病患者,按肺高压状态分为四组。新发肺高压和持续肺高压与年龄性别校正后死亡风险分别增加51%和37%相关,而肺高压缓解组生存率最有利;移植前后收缩期肺动脉压每增加10 mm Hg,死亡风险增加21%,验证队列结果可重复。

要点

  • 肾移植前后新发或持续肺高压与死亡风险增加独立相关。
  • 移植前后收缩期肺动脉压升高与死亡风险连续增加相关。
  • 肺高压轨迹可能作为肾移植候选者风险分层的生物标志物。

核心结论

  • 在因肾移植转诊并接受血流动力学评估的终末期肾病患者中,结局与肺动脉压轨迹强烈相关。
  • 肺动脉压可能作为肾移植候选资格风险分层的新型生物标志物,支持前瞻性研究探讨肺高压在临床决策中的作用。

研究设计与样本

  • 回顾性分析退伍军人健康系统中肾移植前后均有超声心动图肺动脉压值的患者。
  • 主要队列631例,年龄60±6岁,96%男性。
  • 按肺高压状态(收缩期肺动脉压>35 mm Hg)分为无肺高压、新发肺高压、肺高压缓解和持续肺高压四组。
  • 结果在性别平衡的范德堡大学医学中心验证队列中使用超声心动图和右心导管验证。

主要发现

  • 主要队列中持续肺高压231例(36.6%)、无肺高压184例(29.2%)、肺高压缓解133例(21.1%)、新发肺高压83例(13.1%)。

临床怎么用

  • 对终末期肾病肾移植候选者,应关注移植前后肺动脉压的动态变化而非单次测量。
  • 新发或持续肺高压提示死亡风险升高,肺高压缓解提示预后较好。
  • 肺动脉压轨迹可能辅助肾移植候选资格的风险分层,但需前瞻性研究验证。

局限性

  • 回顾性研究设计。
  • 主要队列以男性为主(96%),外推需谨慎。
  • 肺高压定义基于超声收缩期肺动脉压>35 mm Hg。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary hypertension (PH) is a high-risk finding in end-stage kidney disease (ESKD) and is independently associated with increased mortality. RESEARCH QUESTION: What is the relationship between pulmonary artery pressure (PAP) trajectories from before kidney transplantation (KT) to after KT, as well as the role of PH after KT? STUDY DESIGN AND METHODS: We retrospectively analyzed patients in the Veterans Affairs Healthcare System with PAP values both before KT and after KT using echocardiography. The primary exposure was all-cause mortality, stratified according to PH status (systolic PAP > 35 mm Hg) into four groups: No-PH (no PH pre-KT or post-KT), New-PH (no PH pre-KT but PH post-KT), Resolved-PH (PH pre-KT but no PH post-KT), and Persistent-PH (PH pre-KT and post-KT). Findings were validated in the sex-balanced Vanderbilt University Medical System using echocardiography and right heart catheterization. RESULTS: From 631 patients (aged 60 ± 6 years; 96% male) in the primary cohort, there were 231 (36.6%), 184 (29.2%), 133 (21.1%), and 83 (13.1%) patients in the Persistent-PH, Never-PH, Resolved-PH, and New-PH groups, respectively. New-PH and Persistent-PH were associated with a 51% (hazard ratio [HR], 1.51; 95% CI, 1.06-2.15; P = .023) and 37% (HR, 1.37; 95% CI, 1.03-1.82; P = .029) increase in age- and sex-adjusted mortality risk compared with No-PH. Of all groups, Resolved PH was associated with the most favorable survival rate (adjusted HR, 0.73; 95% CI, 0.51-1.05; P = .087, compared with No-PH). Longitudinal mortality risk increased continuously with ≥ 1 mm Hg PAP increase from pre-KT to post-KT. Overall, a 21% increase in mortality risk per 10 mm Hg increment increase in echocardiographic systolic PAP (sPAP) was observed from pre-KT to post-KT, adjusted for age, sex, and baseline sPAP (HR, 1.21; 95% CI, 1.11-1.31; P < .001); a 10 mm Hg sPAP decrease was associated with a 17% decrease in adjusted mortality risk (HR, 0.83; 95% CI, 0.76-0.90; P < .001). Results were reproducible in the validation cohort. INTERPRETATION: Our results indicate that in patients with ESKD referred for KT as well as hemodynamic assessment, outcome is strongly associated with PAP trajectory. These data suggest that PAP may be a novel biomarker for risk stratifying KT candidacy, supporting prospective ESKD studies investigating the role of PH in clinical decision-making.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Zeder K, Kundu S, Siew ED, et al. Longitudinal Pulmonary Arterial Pressure Trajectories and Clinical Outcome in Kidney Transplantation Patients. Chest. 2025. PMID: 40449880. doi:10.1016/j.chest.2025.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。